FDA crackdown on Cipla Pharma's Pune unit, license cancelled over 'unauthorised promotional text'
The FDA seized Reactin Plus stock worth ₹11.19 lakh and ordered the firm to recall the drug from the market.
We haven't written up this one. Hindustan Times has the full story — the link below goes straight to it.
Also reported by 3 other outlets
- Maharashtra FDA Cancels Drug Sale Licences Of Cipla Pharma & Life Sciences’ Pune C&F Unit Over Reactin Plus Irregularities freepressjournal.in
- FDA cancels Cipla pharma’s CFA drug sale licence in Pune indianexpress.com
- Maharashtra FDA cancels licence of Cipla's Pune unit economictimes.indiatimes.com
